跳至主要内容
临床试验/DRKS00003261
DRKS00003261已完成4 期

Efficacy and safety of Neurodoron in patients with nervous exhaustion – a randomized, double-blind, placebo-controlled clinical trial –

WELEDA AGBereich Medizin/Medical Affairs0 个研究点目标入组 204 人开始时间: 2011年9月15日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
204

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • 1. Informed consent
  • 2. At least 18 years of age
  • 3. Confirmed diagnosis of nervous exhaustion according to the definition for neurasthenia as laid down in the WHO-criteria for research, characterized by either A.1 or A.2:
  • A.1 Persistent and distressing complaints of feelings of exhaustion after minor mental effort (such as performing or attempting to perform every-day tasks that do not require unusual mental effort),
  • A.2 Persistent and distressing complaints of feelings of fatigue and bodily weakness after minor physical effort
  • and B. at least one of the following symptoms:
  • feelings of muscular aches and pains, dizziness, tension headaches, sleep disturbance, inability to relax, irritability.
  • C. Inability to recover from A.1 or A.2 by normal periods of rest, relaxation or entertainment.
  • D. The duration of the disorder is at least 3 months.

排除标准

  • 1. Concurrent or previous participation in clinical trials with trial drugs or other treatments for nervous exhaustion
  • 2. Known hypersensitivity against wheat starch
  • 3. Organic disease responsible for exhaustion (e.g. known heart, kidney or liver disease, uncontrolled diabetes mellitus, infection, iron deficiency anaemia, hypothyreotic metabolic situation)
  • 4. Neuro-psychiatric disease causing exhaustion (e.g. psychosis, schizophrenia, dementia)
  • 5. Organic brain syndrome (e.g. postencephalitic syndrome, sequelae of traumatic brain injury)
  • 6. Presumed major depression, defined by BDI-II (Beck Depression Inventory) =29
  • 7. Presumed major panic disorder or generalised anxiety disorder defined by GAD-7-score =16
  • 8. Concomitant medication interfering with IMP, e.g. other drugs for treatment of stress/exhaustion/burnout, antidepressants or benzodiazepines during the last 4 weeks, initiation of treatment with oral beta-adrenoreceptorblockers
  • 9. Known alcohol or drug abuse or dependency
  • 10. Placement in an institution due to official directive or judicial order
  • 11. Pregnancy, lactation

研究者

发起方
WELEDA AGBereich Medizin/Medical Affairs

相似试验